Imaging Cardiovascular Inflammation in the COVID-19 Era
Open Access
- 18 June 2021
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 11 (6), 1114
- https://doi.org/10.3390/diagnostics11061114
Abstract
Cardiac complications are among the most frequent extrapulmonary manifestations of COVID-19 and are associated with high mortality rates. Moreover, positive SARS-CoV-2 patients with underlying cardiovascular disease are more likely to require intensive care and are at higher risk of death. The underlying mechanism for myocardial injury is multifaceted, in which the severe inflammatory response causes myocardial inflammation, coronary plaque destabilization, acute thrombotic events, and ischemia. Cardiac magnetic resonance (CMR) imaging is the non-invasive method of choice for identifying myocardial injury, and it is able to differentiate between underlying causes in various and often challenging clinical scenarios. Multimodal imaging protocols that incorporate CMR and computed tomography provide a complex evaluation for both respiratory and cardiovascular complications of SARS-CoV2 infection. This, in relation to biological evaluation of systemic inflammation, can guide appropriate therapeutic management in every stage of the disease. The use of artificial intelligence can further improve the diagnostic accuracy of these imaging techniques, thus enabling risk stratification and evaluation of prognosis. The present manuscript aims to review the current knowledge on the possible modalities for imaging COVID-related myocardial inflammation or post-COVID coronary inflammation and atherosclerosis.This publication has 121 references indexed in Scilit:
- Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational studyCardiovascular Research, 2019
- Markers of Atherosclerosis: Part 1 – Serological MarkersNew Zealand Medical Journal, 2018
- Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialJournal of the American Heart Association, 2017
- Biomarkers in Stable Coronary Artery DiseaseCurrent Pharmaceutical Biotechnology, 2017
- Detecting human coronary inflammation by imaging perivascular fatScience Translational Medicine, 2017
- Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive reviewJournal of Cardiovascular Magnetic Resonance, 2016
- Inflammation and plaque vulnerabilityJournal of Internal Medicine, 2015
- Perivascular adipose tissue as a cause of atherosclerosisAtherosclerosis, 2011
- Evaluating the Quality of Research into a Single Prognostic Biomarker: A Systematic Review and Meta-analysis of 83 Studies of C-Reactive Protein in Stable Coronary Artery DiseasePLoS Medicine, 2010
- SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARSEuropean Journal of Clinical Investigation, 2009